Credits: Canva
Until law, GLP-1 drugs were used to treat diabetes, obesity and even the recent evidences suggest that it could as well be used to treat chronic kidney problems. There is yet another research, published in JAMA Psychiatry on February 25, titled Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial that explores if GLP-1 receptor agonist semaglutide reduce alcohol consumption and cravings in adults with alcohol use disorder.
The research was conducted over a period of 9 weeks, where in the randomized clinical trial, the participants who were administered semaglutide, it led to reductions in some but not all measures of weekly consumptions. It also reduced weekly alcohol and craving related to placebo, and also led to a greater relative reduction in cigarettes per day.
The research also found that weekly injections of semaglutide, which is the active ingredient in weight loss drugs like Wegovy also helped reduce cravings in people with alcohol use disorder.
The lead author Christian Hendershot said that these findings will help in developing new approaches to treat alcoholism. "Two drugs currently approved to reduce alcohol consumption aren't widely used. The popularity of Ozempic and other GLP-1 receptor agonists increases the chances of broad adoption of these treatments for alcohol use disorder," said Hendershot in news release by the University of Southern California's Institute for Addiction Research, where he is the director.
The study is government-funded research and was funded by the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health.
The study was small, and took in account for only 48 adults over two months, thus experts say that it is not yet clear how safe these drugs are for people who do not need to lose weight. Though the results do add up with the evidence form animal studies on drugs like Ozempic and Wegovy on how it helps manage cravings, not just for food, but also for tobacco and alcohol. Scientists are also studying these drugs on smokers, people with opioid addiction and cocaine users.
Co-author Dr Klara Klein of the University of North Carolina at Chapel Hill who treats people with obesity and diabetes said, "This is such promising data. And we need more of it. We frequently will hear that once people start these medications that their desire to drink is very reduced, if not completely abolished."
The GLP-1 receptor agonists work by mimicking hormones GLP-1 in the gut and brain that regulates appetite and feelings of fullness. This response is what helps one lose weight, and what helps one curb their craving for alcohol. These drugs that mimic the functioning of your brain, which is responsible to tell your body when to stop consuming, are the same hormones that tell your body about other kinds of consumptions, including alcohol. Therefore by consuming the weight loss drugs one can treat alcohol use disorder.
However, the researchers have pointed out on the limited data on the research and have suggested to continue using the three approved drugs by the National Institute on Alcohol Abuse and Alcoholism and Substance Abuse and Mental Health Services Administration, namely, Disulfiram, Naltrexone, and Acamprosate to treat alcohol use disorder until large studies confirm these findings.
Credit: iStock
Two researchers working at the National Institutes of Health (NIH) have been charged with allegedly bringing a deactivated mpox virus into the United States from the Republic of the Congo without a permit.
In a statement, the Department of Justice said Vincent Munster and Claude Kwe, from the NIH's Rocky Mountain Laboratory, were charged in a criminal complaint with conspiracy to smuggle monkeypox into the United States and making false statements to federal law enforcement agencies.
"These NIH experts apparently broke our laws by smuggling viral pathogens on a packed commercial airplane from an outbreak in the Republic of Congo. Let that sink in," said United States Attorney Jerome F. Gorgon Jr.
According to the criminal complaint, Vincent Munster, 53, a citizen of the Netherlands, is the Chief of the Virus Ecology Section in the Laboratory of Virology at the Rocky Mountain Laboratory in Hamilton, Montana.
Claude Kwe, 38, a citizen of Cameroon, is a research fellow in Munster's section.
Both researchers worked on emerging viral pathogens and how those pathogens cross the species barrier. They work at a Biosafety Level 4 laboratory, which employs the highest level of biosafety precautions for scientific research involving known and potential human pathogens.
Also read: Western Australia Records 22 Mpox Infections In 2026; Seven Reported Last Week
According to the US Department of Justice, the researchers were carrying a large black plastic case containing 113 vials when they arrived at Detroit Metropolitan Airport from the Republic of the Congo on January 25, this year. Congo was experiencing a monkeypox outbreak at the time.
Customs and Border Protection (CBP) officers inspected and interviewed the researchers, who were carrying a large black plastic case.
"Munster and Kwe falsely told CBP officers that the black case contained diagnostics and testing equipment," the Department of Justice alleged. But when the FBI and CBP inspected the case and found 113 vials.
As per the investigators:
"No researchers should believe their positions, credentials, or professional status place them above the law," said Jennifer Runyan, Special Agent in Charge of the FBI Detroit Field Office.
"The allegations in this case are serious. They involve the dangerous and unlawful smuggling of deactivated Mpox virus into the United States and alleged efforts to mislead our federal agents," she added.
Read More: Bangladesh's Measles Crisis Deepens: Nearly 600 Children Dead Since March, Infections Set To Surge
Marcus L. Sykes, Special Agent in Charge at the Department of Health and Human Services Office of Inspector General (HHS OIG), said that "any deliberate effort to conceal and smuggle biological materials into the United States without proper authorization was a breach of public trust and could have placed the public at risk".
As per the officials, Munster and Kwe each face a maximum sentence of five years in prison if convicted. The investigation remains ongoing.
Mpox is a viral disease caused by the monkeypox virus, which belongs to the same family of viruses as smallpox.
The virus spreads through close physical contact with an infected person, contaminated materials, or infected animals.
The illness generally lasts between two and four weeks and resolves on its own. However, severe disease can occur, particularly in children, pregnant women, and people with weakened immune systems.
Complications may include secondary infections, respiratory problems, and, in rare cases, death.
Credit: Canva
Chronic kidney disease (CKD) — a progressive condition in which the kidneys become permanently damaged and lose their ability to filter blood effectively — affects an estimated 788 million to 844 million adults worldwide, according to new research published by The Lancet journal today.
The three-part research series, led by global teams from India, the UK, China, Austria, and other countries, projects CKD to become the fifth leading cause of death globally by 2040.
Experts identified limited access to testing, particularly in low- and middle-income countries, the absence of symptoms in the early stages of the disease, and the growing burden of non-communicable diseases as key factors driving the rise in CKD cases worldwide. They also called for sustained investment in diagnosis, treatment, and healthcare infrastructure to address the growing challenge.
The researchers stressed that significant underdiagnosis of chronic kidney disease is a key factor endangering millions of patients worldwide.
Another concern is that mild and moderate stages of the disease often go undetected. Symptoms may develop only in the most severe stages, close to the time when dialysis or a kidney transplant may be required. Without successful treatment, the condition can be fatal.
The lack of symptoms likely contributes to low rates of diagnosis and awareness, said the experts in the research.
"Chronic kidney disease remains one of the most concerning conditions currently impacting global health. The overriding message from our series of research papers is that there remains a pressing need for attention and resources to be focused on this condition," said lead author Dr. Jennifer Lees, Senior Clinical Research Fellow at the University of Glasgow, UK.
Also read:16 Million Indians Die Due To Hypertension Every Year: AIIMS Doc
"There is huge potential to improve early diagnosis, treatment, and healthy lifespan by testing urine for protein routinely across a range of healthcare settings. This may be particularly important in those most at risk of underdiagnosis, including non-white populations and women," she added.
The three research papers, presented at the ongoing European Renal Association Congress in Glasgow, Scotland, highlight that diabetes, hypertension, obesity, and cardiovascular disease are among the major drivers of CKD, with the risk of developing the disease increasing with age.
While CKD can affect anyone, it is more common in people who are Black or of South Asian origin. Compared with those without the condition, people with chronic kidney disease are more likely to be hospitalized, develop complications while in hospital, and be readmitted.
The studies also highlighted differences in diagnosis and treatment between men and women, alongside the need for integrated approaches to CKD prevention and treatment across a range of healthcare settings.
Read More: Emma Barnett: It Took 21 Years To Diagnose My Endometriosis
The experts called for a renewed focus on CKD diagnosis and treatment.
"Chronic kidney disease affects 844 million people worldwide, yet access to even basic kidney testing remains deeply uneven," said Professor Luxia Zhang from Peking University, China.
"Advances in biomarkers, biopsy, and genetic testing now allow us to understand why an individual has kidney disease, not just that they have it. Realizing this benefit for patients everywhere will require sustained investment in diagnostics, laboratory capacity, and workforce," Zhang added.
Credit: iStock
In a major relief amid the ongoing Ebola outbreak, the World Health Organization (WHO) said the number of suspected cases has dropped to 116 after hundreds were ruled out following investigation.
Earlier, the number of suspected cases had neared 1,000 in the Democratic Republic of Congo (DRC).
The global health agency said on Tuesday that there had been 48 deaths and six recoveries in Congo, Reuters reported.
In Uganda, there have been nine confirmed cases and one associated death, WHO spokesperson Christian Lindmeier told reporters in Geneva.
Later, Uganda's Ministry of Health confirmed six additional Ebola cases, bringing the country's total number of confirmed infections to 15.
The ministry said in a statement on X that all six newly confirmed cases were among contacts of previously confirmed patients.
Lindmeier explained that the latest figures were significantly lower because hundreds of suspected cases had been discounted after further investigation.
"They have been cleared out and have either other diseases or have just had a fever and nothing else," he said.
Lindmeier added that the numbers would continue to fluctuate as more people are tested.
A suspected case includes anyone identified through surveillance systems or presenting with symptoms at a health facility. Confirmed cases include only those who test positive for the Bundibugyo strain of Ebola.
Last week, the WHO reported 906 suspected Bundibugyo Ebola cases in Congo, including 223 suspected deaths under investigation.
Subsequently, Jean Kaseya, Director-General of the Africa Centres for Disease Control and Prevention, told the Financial Times that more than 1,100 suspected cases were being investigated.
Testing has posed a major challenge during the outbreak because the commonly used Ebola diagnostic tests initially failed to detect the Bundibugyo strain, for which there is currently no approved vaccine.
Meanwhile, the US Centers for Disease Control and Prevention (CDC) website also listed 116 suspected cases and noted: "On May 29, the DRC Ministry of Health updated their total suspect case count to remove suspected cases that have been ruled out after investigation and suspected deaths that are pending the results of ongoing investigation."
Also read: Western Australia Records 22 Mpox Infections In 2026; Seven Reported Last Week
The United States' plan to establish an Ebola treatment facility in Kenya has sparked public concern about cross-border infection risks and triggered protests.
The proposed 50-bed isolation centre would be staffed by US medical personnel and is intended to treat US citizens affected by the Ebola outbreak in the Democratic Republic of Congo.
Asked about the proposal during a White House briefing, Dr. Mehmet Oz, administrator of the Centers for Medicare & Medicaid Services, said keeping affected Americans closer to the outbreak zone would help speed up treatment.
"You have a golden hour in many of these instances around trauma, but for illnesses, it’s also relatively short, so we are confident, and the State Department’s working on this diligently, that they are going to be able to work out something with Kenya. There has already been a fair amount of communication around this issue," Oz said.
Although Kenya has not recorded any Ebola cases, the proposed quarantine facility has raised fears among residents who believe it could increase the risk of exposure to the virus.
© 2024 Bennett, Coleman & Company Limited